<DOC>
	<DOCNO>NCT01794507</DOCNO>
	<brief_summary>The primary objective study assess safety profile , characterize pharmacokinetics ( PK ) determine dose schedule , maximum tolerate dose ( MTD ) , recommend phase two dose ( RPTD ) ABT-199 administered subject relapse /refactory multiple myeloma receive bortezomib dexamethasone standard therapy .</brief_summary>
	<brief_title>A Study Evaluating ABT-199 Multiple Myeloma Subjects Who Are Receiving Bortezomib Dexamethasone Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 1 Diagnosis multiple myeloma previously treat least 1 prior line therapy ( dose escalation ) ( safety expansion ) receive treatment proteasome inhibitor IMiD ( r ) immunomodulatory agent ( e.g. , thalidomide , lenalidomide ) . Induction therapy follow stem cell transplant consider single line therapy . Measurable disease Screening : Serum monoclonal protein great equal 1 g/dL protein electrophoresis , great equal 200 mg monoclonal protein urine 24hr electrophoresis , serum immunoglobulin free light chain great equal 10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio . Subject history autologous allogenic stem cell transplant , adequate bone marrow independent growth factor support , recover transplant relate toxicity ( ) ; either great 100 day postautologous transplant ( prior first dose study drug ) great equal 6 month postallogenic transplant ( prior first dose study drug ) active graftversushost disease ( i.e. , require treatment ) . Subject must adequate coagulation , renal , hepatic function , per laboratory reference range Screening . Exhibits evidence clinically significant uncontrolled condition ( ) , include , limited : uncontrolled systemic infection ( viral , bacterial , fungal ) , diagnosis fever neutropenia within 1 week prior first dose study drug Cardiovascular disability status New York Heart Association Class great 2 . Class 2 define cardiac disease patient comfortable rest ordinary physical activity result fatigue , palpitation , dyspnea anginal pain . Significant history renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , cardiovascular , pulmonary hepatic disease , opinion investigator , would adversely affect his/her participation study . History active malignancy multiple myeloma within past 3 year prior study entry , follow exception : adequately treat situ carcinoma cervix uterus , basal cell carcinoma skin localize squamous cell carcinoma skin , previous malignancy confine surgically resect ( treated modality ) curative intent . Tested positive HIV hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapsed/refractory multiple myeloma</keyword>
	<keyword>relapse multiple myeloma</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>